Wealth Enhancement Advisory Services LLC Boosts Stock Holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Wealth Enhancement Advisory Services LLC grew its stake in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 55.4% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 108,945 shares of the biopharmaceutical company’s stock after buying an additional 38,850 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Sangamo Therapeutics were worth $94,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Renaissance Technologies LLC raised its stake in shares of Sangamo Therapeutics by 58.8% in the 2nd quarter. Renaissance Technologies LLC now owns 4,126,577 shares of the biopharmaceutical company’s stock valued at $1,479,000 after acquiring an additional 1,528,600 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Sangamo Therapeutics in the 1st quarter valued at approximately $331,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Sangamo Therapeutics during the 2nd quarter valued at $89,000. Vontobel Holding Ltd. grew its holdings in Sangamo Therapeutics by 412.3% during the 3rd quarter. Vontobel Holding Ltd. now owns 300,000 shares of the biopharmaceutical company’s stock worth $259,000 after acquiring an additional 241,440 shares in the last quarter. Finally, Marshall Wace LLP increased its position in shares of Sangamo Therapeutics by 56.3% in the 2nd quarter. Marshall Wace LLP now owns 576,219 shares of the biopharmaceutical company’s stock worth $207,000 after purchasing an additional 207,476 shares during the last quarter. 56.93% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. HC Wainwright increased their price target on shares of Sangamo Therapeutics from $5.00 to $10.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. StockNews.com assumed coverage on Sangamo Therapeutics in a report on Sunday, July 28th. They set a “sell” rating on the stock.

Sangamo Therapeutics Stock Performance

Shares of NASDAQ:SGMO opened at $2.71 on Wednesday. The company’s fifty day moving average is $1.24 and its two-hundred day moving average is $0.83. Sangamo Therapeutics, Inc. has a 1-year low of $0.29 and a 1-year high of $3.18. The stock has a market capitalization of $564.28 million, a price-to-earnings ratio of -1.96 and a beta of 1.10.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.